Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
JNJ-75348780 is a bi-specific antibody targeting CD3 and CD22, which may lead to cytotoxic immune response against B-cell tumors (NCI Thesaurus).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|JNJ-75348780||CD22 Immune Cell Therapy 11 CD3 Antibody 78||JNJ-75348780 is a bi-specific antibody targeting CD3 and CD22, which may lead to cytotoxic immune response against B-cell tumors (NCI Thesaurus).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04540796||Phase I||JNJ-75348780||A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)||Recruiting||USA | FRA | ESP||5|